uniQure Announces Results for the Third Quarter of 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
uniQure Announces Results for the Third Quarter of 2014

Amsterdam, The Netherlands, Dec. 1, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE ), a leader in human gene therapy, today announced results for the third quarter of 2014.

Corporate Highlights and Pipeline Program Updates

  • Hemophilia B Program - uniQure is finalizing all regulatory, trial site and administrative preparations for the initiation of its Phase 1/2 clinical trial in hemophilia B. The Company expects to complete these efforts as planned by the end of 2014 and anticipates the dosing of the first patient to be announced in early 2015. The Company still expects to announce initial results in mid-2015.
  • Glybera ® (alipogen tiparvovec) - uniQure's commercialization partner Chiesi confirmed that the first commercial treatment of a LPLD patient with Glybera will occur in the last quarter of 2014/first quarter 2015.
  • Collaborator-sponsored Pipeline Programs - In October, top-line results from the Phase 1 clinical trial in acute intermittent porphyria (AIP) confirmed the safety and successful transduction of patients' liver cells with the porphobilinogen deaminase gene (PBGD) using uniQure's proprietary AAV5 viral vector, corroborating the interim analysis presented in the second quarter of 2014. These data were presented by the AIPGENE Consortium, a pan-European collaboration supported by the EU Seventh Framework Programme, at the European Society of Gene and Cell Therapy (ESGCT) and Netherlands Society of Gene and Cell Therapy (NVGCT) Collaborative Congress. In the ongoing Parkinson's disease clinical trial conducted by uniQure's partners at UCSF and NIH, the sixth and final patient in the first dose cohort has been treated.
  • Lexington, Massachusetts Manufacturing Facility - Approximately 40 employees have initiated preparations for production of the first GMP batch expected in H1 2015.
  • InoCard Acquisition - uniQure has completed the integration of the German cardiology gene therapy company Inocard, acquired in July 2014, which is now called uniQure Germany GmbH.

Jörn Aldag, uniQure Chief Executive Officer, commented: "uniQure continues to direct key resources toward advancing the Company's core programs, most prominently hemophilia B, where we expect to announce preliminary safety and efficacy data in mid-2015, and our earlier-staged hemophilia A and congestive heart failure preclinical development programs."

Financial Highlights

As of September 30, 2014, the Company held cash and cash equivalents of €62.8 million. Total revenues (consisting of licensing and collaboration revenues) for the three months ended September 30, 2014 were €1.0 million, compared with €1.3 million in the same period of 2013. For the nine months ended September 30, 2014, total revenues were €3.2 million, compared to €2.1 million in the first nine months of 2013. Collaboration revenues represent development activities that are reimbursable by Chiesi under the Company's co-development agreement for hemophilia B. License revenues represent the monthly amortization of the upfront payments received under the Chiesi agreements related to Glybera ® entered into in June 2013.

Research and development expenses were €9.5 million for the three months ended September 30, 2014, compared to €3.2 million for the same period in 2013. Research and development expenses for the nine months ended September 30, 2014 were €23.7 million, compared to €9.6 million for the same period in 2013. The increase in research and development expenses reflect additional development and clinical activities required to support the planned commercial launch of Glybera ® , in addition to the continued progression of uniQure's other programs through late stage research and early clinical development.

Net loss for the three months ended September 30, 2014 was €9.1 million or €0.51 per share, compared to €7.0 million or €0.61 per share for the same period in 2013. Net loss for the nine months ended September 30, 2014 was €25.9 million or €1.54 per share, compared to €20.0 million or €1.94 per share for the same period in 2013. Net loss for both the three and nine months ended September 30, 2014 was affected by a favourable €3.6 million related to foreign exchange results.

For further financial information for the period ending September 30, 2014, please refer to the financial statements appearing at the end of this release.

Webcast

uniQure will host an Investor Day in New York City and simultaneous webcast on December 1, 2014, at 8:30 am ET to provide a detailed update on the Company's programs as well as a discussion on the future of gene therapy with distinguished guest speakers. To access the webcast, log on to http://www.media-server.com/m/p/tfx7rb2k or go to the "Events" section on the "Media" page of uniQure's website, at http://www.uniqure.com/news/calendar-of-events . A replay of the webcast will be available on uniQure's website for at least 30 days following the event.

About uniQure

uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the timeframe and anticipated results of our research and development programs and those of our collaborators, as well as the commercial success of Glybera.. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, including the risk of cessation or delay of any of our ongoing or planned clinical studies and/or development of our product candidates; the risk of delay or failure to successfully commercialize or obtain or maintain regulatory approval of our products; risks related to our manufacturing processes and facilities, including our compliance with applicable regulatory requirements; the risk that our collaborations or our other collaboration partners will not continue or will not be successful; risks related to regulatory oversight, including our compliance with post-approval requirements; risks related to product commercialization; risks related to intellectual property claims; and the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Form 20-F filed with the Securities and Exchange Commission dated April 25, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure:                                                                     Aicha Diba                                                                 
Investor Relations                                                     
Phone: +31 20 240 6100                                        
a.diba@uniQure.com                                                               

Media inquiries: Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
gschweitzer@macbiocom.com

UNIQURE N.V.

Unaudited Condensed Consolidated Balance Sheets (€ in thousands)

      DECEMBER 31,   SEPTEMBER, 30  
      2013   2014  
Assets            
Non-current assets            
Goodwill     -   1,342  
Other Intangible assets, net     7,775   15,311  
Property, plant and equipment     2,614   17,055  
Other non-current assets     923   978  
Total non-current assets     11,312   34,686  
Current assets            
Receivables from related parties     1,425   1,138  
Trade and Other Receivables     1,557   2,188  
Inventories     865   539  
Cash and cash equivalents     23,810   62,782  
Total current assets     27,657   66,647  
Total assets     38,969   101,333  
Equity            
Share capital     610   892  
Share premium     142,459   205,811  
Other reserves     6,536   14,422  
Accumulated deficit     (144,041)   (169,920)  
Total equity     5,564   51,205  
Liabilities            
Non-current liabilities            
Borrowings     6,292   15,684  
Financial lease liabilities     302   177  
Deferred rent     680   5,525  
Deferred revenue     15,679   15,017  
Deferred Tax Liabilities     -   1,379  
Contingent Considerations     -   1,301  
Total non-current liabilities     22,953   39,083  
Current liabilities            
Trade and other payables     7,601   8,924  
Debt to related party - derivative     722   272  
Borrowings     633   -  
Borrowings - derivative     217   93  
Deferred rent     -   451  
Deferred revenue     1,279   1,305  
Total Current Liabilities     10,452   11,045  
Total liabilities     33,405   50,128  
Total equity and liabilities     38,969   101,333  

 

UNIQURE N.V.

Unaudited Condensed Consolidated Statements of Comprehensive Loss (€ in thousands, except share and per share data)

      THREE MONTHS ENDED   NINE MONTHS ENDED  
      SEPTEMBER 30,   SEPTEMBER 30,  
      as restated       as restated      
      2013   2014   2013   2014  
      (€ in thousands)              
License revenues     220   221   220   662  
Collaboration revenues     1,073   780   1,831   2,551  
Total revenues     1,293   1,001   2,051   3,213  
Cost of goods sold     -   -   (800 ) -  
Other income     171   208   562   598  
Research and development expenses     (3,152 ) (9,514 ) (9,573 ) (23,740 )
Selling, general and administrative expenses     (3,394 ) (3,218 ) (7,551 ) (8,035 )
Other gains / losses, net     (304 ) 3,630   (269 ) 3,694  
Total Operating Costs     (6,679 ) (8,894 ) (16,831 ) (27,483 )
Operating result     (5,386 ) (7,893 ) (15,580 ) (24,270 )
Finance income     4   54   48   125  
Finance expense     (1,656 ) (1,220 ) (4,470 ) (1,734 )
Finance income/(expense)-net     (1,652 ) (1,166 ) (4,422 ) (1,609 )
Result before corporate income tax     (7,038 ) (9,059 ) (20,002 ) (25,879 )
Corporate income taxes     -   -   -   -  
Net Loss     (7,038 ) (9,059 ) (20,002 ) (25,879 )
Items that may be subsequently reclassified to profit or loss     6   703   6   693  
Other comprehensive income     6   703   6   693  
Total comprehensive loss     (7,032 ) (8,356 ) (19,996 ) (25,186 )
Loss per share attributable to the equity holders of the Company during the year                    
Basic and diluted loss per share     (0.61 ) (0.51 ) (1.94 ) (1.54 )

 

UNIQURE N.V.

Unaudited Condensed Consolidated Statement of Changes in Equity/Deficit (€ in thousands)

      Total                  
      Share   Share   Other   Accumulated   Total  
      Capital   Premium   Reserves   Deficit   Equity/Deficit  
Balance at January 1, 2013     483   114,795   1,508   (117,234 ) (448 )
Result for the period     -   -   -   (20,002 ) (20,002 )
Other Comprehensive Income             -   6   6  
Capital contributions     127   27,649   -   -   27,776  
Result on conversion of the loan     -   -   3,005   -   3,005  
Share based payment/expense     -   -   1,411       1,411  
Balance at September 30, 2013 (as restated)     610   142,444   5,924   (137,230 ) 11,748  
Result for the period     -   -   -   (6,818 ) (6,818 )
Other Comprehensive Income     -   -   -   7   7  
Capital contributions     -   15   -   -   15  
Result on conversion of the loan     -   -   -   -   -  
Share based payment/expense     -   -   612   -   612  
Balance at December 31, 2013     610   142,459   6,536   (144,041 ) 5,564  
Result for the period     -   -   -   (25,879 ) (25,879 )
Other Comprehensive Income     -   -   693   -   693  
Proceeds from shares issued     282   64,020   -   -   64,302  
Share issuance costs     -   (668 ) -   -   (668 )
Share based payment/expense     -   -   7,193   -   7,193  
Balance at: September 30, 2014     892   205,811   14,422   (169,920 ) 51,205  

 

UNIQURE N.V.

Unaudited Condensed Consolidated Statement of Cash Flows (€ in thousands)

    NINE MONTHS ENDED
  SEPTEMBER 30,
  as restated    
  2013   2014
Cash flow from operating activities        
Net loss   (20,002)   (25,879)
Adjustments for:        
Depreciation   398   859
Lease incentive   -   4,854
Derivative result   2,339   (574)
Derivative result arising on early conversion of loan   1,333   -
Exchange result   (4)   (2,545)
Other non-cash items   -   (1)
Share-based expenses   1,411   7,193
Changes in other non-current assets   (917)   -
Changes in trade and other receivables   (1,937)   (142)
Movement in inventories   (427)   326
Changes in trade and other payables   (282)   (1,798)
Changes in deferred revenue and provisions   17,102   (635)
Movement in other liabilities   1,701   1,209
Interest (income) / expense   956   1,035
Cash used in operations   1,671   (16,098)
Interest paid   (17)   (807)
Net cash used in operating activities   1,654   (16,905)
Cash flow from investing activities        
Purchases of property, plant and equipment   (536)   (13,379)
Purchases of intangible assets   (3,623)   (2,129)
Interest received   -   95
Acquisition of businesses   -   (1,463)
Net cash used in investing activities   (4,159)   (16,876)
Cash flow from financing activities        
Capital contribution from shareholders   14,278   -
Proceeds from shares issued   -   62,786
Share issuance cost   -   (668)
Convertible loans drawn down   11,999   -
Proceeds from borrowings   7,492   7,184
Redemption of financial lease   (106)   (116)
Net cash generated from financing activities   33,663   69,186
Net increase in cash, cash equivalents and bank overdrafts   31,158   35,405
Currency effect cash and cash equivalents   6   3,567
Cash, cash equivalents and other bank overdrafts at beginning of the period   263   23,810
Cash, cash equivalents and other bank overdrafts at end of the period   31,427   62,782

HUG#1875580

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 104

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 56

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 63

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 111

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 102

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 59

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 142

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading

Top 5 Most Recently Viewed Articles

Arasan Chip Systems Unveils Advanced eUSB2 Solutions for IoT

Updated Category News Views 300

Arasan's Innovative USB2 Solutions Now Available Arasan Chip Systems, a recognized leader in semiconductor intellectual property for mobile and automotive systems on chips (SoCs), has announced the launch of its new Embedded USB2 (eUSB2) IP Core. This cutting-edge technology aims to empower a wide range of electronic devices with efficient connectivity options. Targeting...

Continue Reading
Class Action Filed Against MongoDB: Key Insights and Impacts

Updated Category News Views 98

Overview of the Class Action Lawsuit Against MongoDB Pomerantz LLP has recently brought attention to a significant legal issue concerning MongoDB, Inc. (NASDAQ: MDB). The law firm has filed a class action lawsuit that raises serious questions about the company's compliance with securities laws and the potential consequences for investors. Allegations Explained This...

Continue Reading
Rycor LLC's Strategic Push in Commercial Heating Solutions

Updated Category News Views 136

Expanding Horizons: Rycor LLC Enters Commercial Market RYCOR LLC, well-known as the Northeast's authority in energy-efficient residential mini-splits, is broadening its horizons to embrace the commercial heating and cooling sector. This strategic move represents a significant enhancement in their service offerings, targeting multi-family housing developments, office...

Continue Reading
Successful Charity Ride Brings Community Together for a Cause

Updated Category News Views 148

Second Annual Solstice Century Ride Makes a Big Impact During the longest day of the year, fifty-two enthusiastic riders took on a 100-mile challenge as they participated in the second annual Solstice Century Ride. The event, held at the picturesque Whalon Lake Forest Preserve, proved to be more than just a cycling challenge; it became a powerful avenue for community...

Continue Reading
QuickBooks' Intelligent AI Tool Revolutionizes Business Insights

Updated Category News Views 126

Revolutionizing Business Insights with Intelligent AI In today's fast-paced business environment, understanding how to leverage technology for better decision-making is crucial. Enter QuickBooks' Intelligent AI Dashboard Agent, a powerful tool that has been recognized by industry experts as the best all-in-one solution for real-time business insights in 2025. This...

Continue Reading